We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Molecular Method Directly Identifies Antigens

By LabMedica International staff writers
Posted on 23 Apr 2012
A novel method for identifying antigens is based on the isolation of T cells present in samples of affected tissues obtained from patients with autoimmune diseases. More...


The genetic blueprints for the specific antigen-binding T-cell receptors (TCRs) produced by these cells, have been transferred into a cultured cell line that grows well in the laboratory and contains a version of the gene for the Green Fluorescent Protein (GFP) that is specifically expressed if a TCR is activated.

Scientists at the Ludwig Maximilians University (Munich, Germany) collaborated with a team from the Max Planck Institute for Neurobiology (Munich, Germany) to develop the new method that can identify the antigens that initiate immune reactions and may help to prevent misdirected attacks in the future. They used genetic engineering techniques, to generate cells that emit green fluorescent light when stimulated by the binding of a cognate antigen.

The T-cells are incubated with a collection of some 100 million peptides, which are short amino acid sequences like those normally recognized by TCRs. If even a single peptide represented in the library is recognized by a specific TCR, the corresponding cell synthesizes GFP and it can be detected by its green fluorescence, allowing the bound antigen to be identified. The method thus provides a relatively simple way of identifying single autoimmune antigens from huge numbers of possible suspects.

An initial test carried out using cells specific for a known influenza antigen confirmed the efficacy of the method. The investigators were able unequivocally to select out and identify the correct antigen from all the other peptides used in the test. The technique is so rapid and so sensitive that several million antigens can be analyzed in a matter of hours. This opens up a wide range of possible applications, ranging from the analysis of the reactive antigens responsible for autoimmune diseases like multiple sclerosis or psoriasis to the identification of new tumor or viral antigens. The practical potential is so significant that the method is the subject of a patent application. The study was published online on April 8, 2012, in the journal Nature Medicine.

Related Links:

Ludwig Maximilians University
Max Planck Institute for Neurobiology



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Automatic Hematology Analyzer
LABAS F9000
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.